Skip to main content

Table 1 Association of FBXW7/hCDC4-β promoter methylation in 161 primary breast cancer patients with clinicopathological features

From: Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer

  UM (%) M (%) P
Age      
≤67 37 (45.1) 45 (54.9) 0.27
>67 43 (54.4) 36 (45.6)  
ER      
Negative 17 (37.7) 28 (62.3) 0.08
Positive 61 (54) 52 (46)  
Unknown 2   1   
PR      
Negative 17 (40) 25 (60) 0.21
Positive 61 (52.5) 55 (47.5)  
Unknown 2   1   
LN      
Negative 41 (50.6) 40 (49.4) 0.75
Positive 36 (47) 40 (53)  
Unknown 3   1   
Grade      
I/II 64 (55.1) 52 (44.9) 0.017
III 13 (32.5) 27 (67.5)  
Unknown 3   2   
Stage      
I/II 58 (52.2) 53 (47.8) 0.18
III 9 (36) 16 (64)  
Unknown 12   12   
  1. * Fisher's exact test. UM, unmethylated; M, methylated; ER, estrogen receptor; PR, progesterone receptor; LN, lymph node.